Cover Image
市場調查報告書

成人用疫苗的全球市場、企業分析 (∼2020年)

Global - Adult Vaccines Market & Company Analysis to 2020

出版商 iGate Research Pvt Ltd 商品編碼 360455
出版日期 內容資訊 英文 232 Pages
訂單完成後即時交付
價格
Back to Top
成人用疫苗的全球市場、企業分析 (∼2020年) Global - Adult Vaccines Market & Company Analysis to 2020
出版日期: 2015年05月11日 內容資訊: 英文 232 Pages
簡介

全球成人用疫苗市場今後5年,預計以約7%的年複合成長率 (CAGR) 成長。為了預防流感等感染疾病,許多人開始響應疫苗接種,及新疫苗的開發等,成為市場成長的主要推動因素。另一方面,對疫苗的安全性的不信任感,及疫苗供給不足、延遲,開發期長,新進入障礙高等,成為今後應解決的課題。

本報告提供全球成人用疫苗市場相關分析,整體市場趨勢,及各地區、各疾病、各企業詳細趨勢 (銷售額、接種人口等成果值和預測值),各公司的產品開發、趨勢,市場成長要素和今後的課題等調查評估。

摘要

第1章 摘要整理

第2章 市場規模的分析與預測 (總計14年份)

  • 成人用疫苗的市場規模與其預測
  • 成人用疫苗的接種者數與其預測

第3章 市場佔有率的分析與預測 (總計11年份)

  • 各疾病的接種者數佔有率與其預測
  • 各疾病的市場佔有率與其預測
  • 各企業的市場佔有率與其預測
  • 各疾病的銷售額佔有率與其預測:企業單位
    • GlaxoSmithKline (GSK)的情況
    • Sanofi Pasteur的情況
    • Merck的情況
    • Novartis的情況
  • 各企業的市場佔有率與其預測:各疾病的趨勢
    • 流感
    • 子宮頸癌症/HPV
    • 肝炎
    • 肺炎球菌
    • 腦膜炎
    • DTP (白喉、破傷風、百日咳)
  • 各地區的市場佔有率與其預測

第4章 各疾病的市場分析 (總計14年份)

  • 流感
    • 市場規模與其預測
    • 接種者數與其預測
    • 給藥數量與其預測
  • 子宮頸癌症/HPV (人類乳突病毒)
  • 帶狀皰疹 (帶狀皰疹)
  • 肺炎球菌
  • 腦膜炎
  • MMRV (麻疹、腮腺炎、德國麻疹、水痘)
  • 肝炎
  • DTP (白喉、破傷風、百日咳)
  • 旅遊用 (地方病)、其他

第5章 各企業的市場分析與策略聯盟趨勢

  • GlaxoSmithKline
    • 成人用疫苗的銷售額與其預測
    • 策略性聯盟的動向
  • Sanofi Pasteur
  • Merck
  • Novartis
  • Pfizer
  • 其他的企業:銷售額與其預測

第6章 各疾病、各企業的銷售額與其預測 (總計14年份)

  • GlaxoSmithKline (GSK)
    • 流感:成人用疫苗的銷售額、預測
    • 子宮頸癌症/HPV:成人用疫苗的銷售額、預測
    • 肝炎:成人用疫苗的銷售額、預測
    • DTP:成人用疫苗的銷售額、預測
  • Sanofi Pasteur
    • 流感:成人用疫苗的銷售額、預測
    • DTP:成人用疫苗的銷售額、預測
    • 腦膜炎:成人用疫苗的銷售額、預測
  • Merck
    • 流感:成人用疫苗的銷售額、預測
    • 子宮頸癌症/HPV:成人用疫苗的銷售額、預測
    • 帶狀皰疹:成人用疫苗的銷售額、預測
    • 腦膜炎:成人用疫苗的銷售額、預測
    • MMRV:成人用疫苗的銷售額、預測
    • 肝炎:成人用疫苗的銷售額、預測
  • Novartis
    • 流感:成人用疫苗的銷售額、預測
    • 腦膜炎:成人用疫苗的銷售額、預測
  • Pfizer
    • 肺炎球菌:成人用疫苗的銷售額、預測

第7章 各地區的市場規模與其預測 (總計10年份)

  • 美國
  • 北美/加勒比海地區
  • 南美
  • 歐洲
  • 日本
  • 印度
  • 中國
  • 其他的國家 (RoW)

第8章 疫苗相關的主要企業收購的動向 (過去11年份)

第9章 成人用疫苗市場推動因素

  • GAVI模式促進疫苗製造商銷售額
    • 夥伴關係模式
    • 經營模式
  • GIVES (全球疫苗接種願景、策略)
  • 美國的疫苗可得性的改善
  • 疫苗受害救濟計劃
  • 疫苗安全性資料的鏈接、計劃
  • 疫苗技術的轉換
  • WHO的全球疫苗行動計劃(2011∼2020年)
  • 對有效的傳播策略的持續性著重

第10章 成人用疫苗市場課題

  • 已經過核准疫苗的最佳利用相關障礙 (技術方面、經濟方面、文化方面)
  • 疫苗開發期間的縮短
  • 疫苗開發、認證制度的複雜性,造成產品開發的障礙
    • 法律上的障礙
    • 一般的、技術的障礙
    • 經濟未來
    • 在法規方面的障礙
  • 疫苗接種的拒絕、阻力
  • 疫苗的不良反應相關報告制度
  • 疫苗的不足和延遲
  • 疫苗的研究開發 (R&D) 的障礙
  • 新加入廠商時的障礙

圖表一覽

目錄

Adults are as likely as children to die from diseases that they can be immunized. For example, vaccination can prevent about 50% of deaths from pneumococcal disease and 80% of deaths from influenza-related complications in the elderly. Adult vaccines continues to be one of the growing segment for pharmaceutical companies. The adult vaccines market has been forecasted to increase at a compound annual growth rate (CAGR) of around 7% over the next five years. The driving factors for adult vaccines growth are an increasing acceptance of adult vaccines and the public health focus on flu prevention, as well as introductions of new vaccines. The vaccines industry also faces hindrances such as vaccine safety, shortages and delays, vaccine development time line as well as entry barriers for new manufacturers.

Adult Vaccines Market - Disease Wise Analysis

The influenza vaccines are the most popular and accepted vaccination amongst adults. It accounted for maximum share of adult vaccines market in 2014. The vaccinations for hepatitis is the second most popular vaccines in 2014. The HPV/Cervical cancer vaccines and pneumococcal vaccines stands at third and fourth spots respectively in adult vaccines market. While vaccines for zoster shingles and DTP are also gaining ground in adult vaccines market landscape.

Adult Vaccines Market - Company Analysis

Note: Novartis divested its non-influenza vaccine business to GlaxoSmithKline (GSK) and CSL acquires Novartis influenza vaccines business.

In 2010, GSK was the leader in the adult vaccines market but it lost the leadership position to Merck. Sanofi Pasteur stands at the second spot in the adult vaccines market. GSK slipped to third position in the global adult vaccines market in 2014. While Pfizer and Novartis is at the fourth and fifth position respectively in the adult vaccines market landscape.

Adult Vaccines Market - Disease Wise Company Sales Analysis

GSK generates maximum adult vaccines sales from Hepatitis and DTP vaccines, while Sanofi Pasteur remains focused on maintaining its leadership in the influenza market. The cervical cancer and zoster shingles vaccines contributes maximum share of the total Merck adult vaccines sales. Novartis main source of adult vaccines sales revenue is the influenza vaccines.

In 2011, Sanofi Pasteur replaced GSK and became the dominant player in influenza vaccine landscape, while in the cervical cancer market, Merck is at the forefront and is expected to maintain its dominancy over a longer period of time. GSK is the clear leader in hepatitis vaccines market.

Adult Vaccines Market - Regional Distribution

On a regional basis the United States comprises the single largest market for adult vaccines being closely followed by Europe. Japan adult vaccines market share is expected to remain flat during the forecasting period. South America and India are competing closely with each other to get the maximum share of the adult vaccines market pie.

iGATE RESEARCH report entitled Global - Adult Vaccines Market and Company Analysis to 2020 is a 232 page report with 142 Figures and 8 Tables. This report studies in detail the adult vaccines market disease wise, company wise sales analysis and strategic alliances, mergers and acquisitions along with growth drivers and hindrances for the vaccines market landscape.

The 9 Diseases covered in the report are analyzed from four viewpoints:

  • 1. Adult Vaccines Market (2007 - 2020)
  • 2. Number of Adults Vaccinated (2007 - 2020)
  • 3. Number of Doses (2007 - 2020)
  • 4. Company Sales Share (2010 - 2020)

The 6 Company covered in the report are analyzed from two viewpoints:

  • 1. Disease Wise - Adult Vaccines Sales (2007 - 2020)
  • 2. Strategic Alliances

The 8 Region covered in the report are analyzed from one viewpoint:

  • 1. Adult Vaccines Market (2011 - 2020)

Global Adult Vaccines Market, Number of Adults Vaccinated and Doses - Disease Wise Analysis to 2020 (9 Disease Analysed)

  • 1. Influenza
  • 2. Cervical Cancer
  • 3. Zoster Shingles
  • 4. Pneumococcal
  • 5. Meningococcal
  • 6. MMRV
  • 7. Hepatitis
  • 8. DTP
  • 9. Travel and Miscellaneous

Global Adult Vaccines Market - Company Analysis to 2020 (6 Company Analysed)

  • 1. GlaxoSmithKline
  • 2. Sanofi Pasteur
  • 3. Merck
  • 4. Novartis
  • 5. Pfizer
  • 6. Other Companies

Global Adult Vaccines Market - Regional Distribution to 2020 (8 Region Analysed)

  • 1. United States
  • 2. North America/Caribbean
  • 3. South America
  • 4. Europe
  • 5. Japan
  • 6. India
  • 7. China
  • 8. Rest of the World

Source of Information

iGATE RESEARCH employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by iGATE Research dedicated team of qualified professionals with deep industry experience and expertise.

Research Methodologies

Primary Research Methodologies: Questionnaires, Surveys, Interviews with Individuals, Small Groups, Telephonic Interview, etc.

Secondary Research Methodologies: Printable and Non-printable sources, Newspaper, Magazine and Journal Content, Government And NGO Statistics, white Papers, Information on the Web, Information from Agencies Such as Industry Bodies, Companies Annual Report, Government Agencies, Libraries And Local Councils and a large number of Paid Databases.

Table of Contents

ABSTRACTSCONTENTSLIST OF FIGURESLIST OF TABLES

1. EXECUTIVE SUMMARY

2. GLOBAL - ADULT VACCINES ANALYSIS AND FORECAST (2007 - 2020)

  • 2.1 Global Adult Vaccines Market and Forecast
  • 2.2 Global Adult Vaccines - Number of Adults Vaccinated and Forecast

3. GLOBAL ADULT VACCINE MARKET SHARE ANALYSIS AND FORECAST (2010 - 2020)

  • 3.1 Global Adult Vaccines - Disease Wise Adults Vaccinated Share and Forecast
  • 3.2 Global Adult Vaccines - Disease Wise Market Share and Forecast
  • 3.3 Global Adult Vaccines - Company Wise Market Share and Forecast
  • 3.4 Companies Adult Vaccines - Disease Wise Sales Share and Forecast
    • 3.4.1 GlaxoSmithKline (GSK) - Adult Vaccines Sales Share and Forecast
    • 3.4.2 Sanofi Pasteur - Adult Vaccines Sales Share and Forecast
    • 3.4.3 Merck - Adult Vaccines Sales Share and Forecast
    • 3.4.4 Novartis - Adult Vaccines Sales Share and Forecast
  • 3.5 Adult Vaccine Disease Wise Market - Company Share and Forecast
    • 3.5.1 Influenza Adult Vaccines - Company Market Share and Forecast
    • 3.5.2 Cervical Cancer/HPV Adult Vaccines - Company Market Share and Forecast
    • 3.5.3 Hepatitis Adult Vaccines - Company Market Share and Forecast
    • 3.5.4 Pneumococcal Adult Vaccines - Company Market Share and Forecast
    • 3.5.5 Meningococcal Adult Vaccines - Company Market Share and Forecast
    • 3.5.6 DTP (Diphtheria, Tetanus, Pertussis) Adult Vaccines - Company Market Share and Forecast
  • 3.6 Global Adult Vaccines Market - Region Wise Share and Forecast

4. GLOBAL ADULT VACCINE MARKET - DISEASE WISE ANALYSIS

  • 4.1 Influenza - Adult Vaccine Analysis and Forecast (2007 - 2020)
    • 4.1.1 Influenza - Adult Vaccine Market and Forecast
    • 4.1.2 Influenza - Number of Adults Vaccinated and Forecast
    • 4.1.3 Influenza - Number of Vaccines Doses and Forecast
  • 4.2 Cervical Cancer/ HPV - Adult Vaccine Analysis and Forecast (2007 - 2020)
    • 4.2.1 Cervical Cancer/ HPV - Adult Vaccine Market and Forecast
    • 4.2.2 Cervical Cancer/ HPV - Number of Adults Vaccinated and Forecast
    • 4.2.3 Cervical Cancer/ HPV - Number of Vaccines Doses and Forecast
  • 4.3 Zoster Shingles - Adult Vaccine Analysis and Forecast (2007 - 2020)
    • 4.3.1 Zoster Shingles - Adult Vaccine Market and Forecast
    • 4.3.2 Zoster Shingles - Number of Adults Vaccinated and Forecast
    • 4.3.3 Zoster Shingles - Number of Vaccines Doses and Forecast
  • 4.4 Pneumococcal - Adult Vaccine Analysis and Forecast (2010 - 2020)
    • 4.4.1 Pneumococcal - Adult Vaccine Market and Forecast
    • 4.4.2 Pneumococcal - Number of Adults Vaccinated and Forecast
    • 4.4.3 Pneumococcal - Number of Vaccines Doses and Forecast
  • 4.5 Meningococcal - Adult Vaccine Analysis and Forecast (2010 - 2020)
    • 4.5.1 Meningococcal - Adult Vaccine Market and Forecast
    • 4.5.2 Meningococcal - Number of Adults Vaccinated and Forecast
    • 4.5.3 Meningococcal - Number of Vaccines Doses and Forecast
  • 4.6 Measles, Mumps, Rubella and Varicella (MMRV) - Adult Vaccine Analysis and Forecast (2010 - 2020)
    • 4.6.1 Measles, Mumps, Rubella and Varicella (MMRV) - Adult Vaccine Market and Forecast
    • 4.6.2 Measles, Mumps, Rubella and Varicella (MMRV) - Number of Adults Vaccinated and Forecast
    • 4.6.3 Measles, Mumps, Rubella and Varicella (MMRV) - Number of Vaccines Doses and Forecast
  • 4.7 Hepatitis - Adult Vaccine Analysis and Forecast (2007 - 2020)
    • 4.7.1 Hepatitis - Adult Vaccine Market and Forecast
    • 4.7.2 Hepatitis - Number of Adults Vaccinated and Forecast
    • 4.7.3 Hepatitis - Number of Vaccines Doses and Forecast
  • 4.8 Diphtheria, Tetanus, Pertussis (DTP) - Adult Vaccine Analysis and Forecast (2007 - 2020)
    • 4.8.1 Diphtheria, Tetanus, Pertussis (DTP) - Adult Vaccine Market and Forecast
    • 4.8.2 Diphtheria, Tetanus, Pertussis (DTP) - Number of Adults Vaccinated and Forecast
    • 4.8.3 Diphtheria, Tetanus, Pertussis (DTP) - Number of Vaccines Doses and Forecast
    • 4.9 Travel and Miscellaneous - Adult Vaccine Analysis and Forecast (2007 - 2020)

5. GLOBAL ADULT VACCINE MARKET - COMPANY ANALYSIS AND STRATEGIC ALLIANCES

  • 5.1 GlaxoSmithKline
    • 5.1.1 GlaxoSmithKline (GSK) - Adult Vaccine Sales and Forecast
    • 5.1.2 Strategic Alliances of GlaxoSmithKline (GSK)
  • 5.2 Sanofi Pasteur
    • 5.2.1 Sanofi Pasteur Vaccines Sales and Forecast
    • 5.2.2 Strategic Alliances of Sanofi Pasteur
  • 5.3 Merck
    • 5.3.1 Merck Vaccines Sales and Forecast
    • 5.3.2 Strategic Alliances of Merck
  • 5.4 Novartis
    • 5.4.1 Novartis Vaccines Sales and Forecast
    • 5.4.2 Strategic Alliances of Novartis
  • 5.5 Pfizer
    • 5.5.1 Pfizer Adult Vaccines Sales and Forecast
    • 5.5.2 Strategic Alliances of Pfizer
  • 5.6 Other Companies Sales and Forecast

6. GLOBAL ADULT VACCINE - DISEASE WISE COMPANY SALES AND FORECAST (2007 - 2020)

  • 6.1 GlaxoSmithKline (GSK) - Adult Vaccines Sales and Forecast
    • 6.1.1 GlaxoSmithKline (GSK) - Influenza Adult Vaccines Sales and Forecast
    • 6.1.2 GlaxoSmithKline (GSK) - Cervical Cancer/HPV Adult Vaccines Sales and Forecast
    • 6.1.3 GlaxoSmithKline (GSK) - Hepatitis Adult Vaccines Sales and Forecast
    • 6.1.4 GlaxoSmithKline (GSK) - DTP Adult Vaccines Sales and Forecast
  • 6.2 Sanofi Pasteur - Adult Vaccines Sales and Forecast
    • 6.2.1 Sanofi Pasteur - Influenza Adult Vaccines Sales and Forecast
    • 6.2.2 Sanofi Pasteur - DTP Adult Vaccines Sales and Forecast
    • 6.2.3 Sanofi Pasteur - Meningococcal Adult Vaccines Sales and Forecast
  • 6.3 Merck - Adult Vaccines Sales and Forecast
    • 6.3.1 Merck/CSL - Influenza Adult Vaccines Sales and Forecast
    • 6.3.2 Merck - Cervical Cancer/HPV Adult Vaccines Sales and Forecast
    • 6.3.3 Merck - Zoster Shingles Adult Vaccines Sales and Forecast
    • 6.3.4 Merck - Pneumococcal Adult Vaccines Sales and Forecast
    • 6.3.5 Merck - MMRV Adult Vaccines Sales and Forecast
    • 6.3.6 Merck - Hepatitis Adult Vaccines Sales and Forecast
  • 6.4 Novartis - Adult Vaccines Sales and Forecast
    • 6.4.1 Novartis - Influenza Adult Vaccines Sales and Forecast
    • 6.4.2 Novartis - Meningococcal Adult Vaccines Sales and Forecast
  • 6.5 Pfizer - Adult Vaccines Sales and Forecast
    • 6.5.1 Pfizer - Pneumococcal Adult Vaccines Sales and Forecast

7. GLOBAL ADULT VACCINE MARKET - REGIONAL DISTRIBUTION (2011 - 2020)

  • 7.1 United States - Adult Vaccine Market and Forecast
  • 7.2 North America/Caribbean - Adult Vaccine Market and Forecast
  • 7.3 South America - Adult Vaccine Market and Forecast
  • 7.4 Europe - Adult Vaccine Market and Forecast
  • 7.5 Japan - Adult Vaccine Market and Forecast
  • 7.6 India - Adult Vaccine Market and Forecast
  • 7.7 China - Adult Vaccine Market and Forecast
  • 7.8 Rest of the World (ROW) - Adult Vaccine Market and Forecast

8. MAJOR VACCINE RELATED ACQUISITIONS (2005-2015)

9. ADULT VACCINES MARKET - DRIVING FACTORS

  • 9.1 GAVI Model Fuelling Vaccine Manufacturers
    • 9.1.1 The Partnership Model
    • 9.1.2 The Business Model
  • 9.2 Global Immunization Vision and Strategy (GIVS)
  • 9.3 Growing Vaccine Availability in United States
  • 9.4 The Vaccine Injury Compensation Program
  • 9.5 The Vaccine Safety Data link Project
  • 9.6 Transformation of Vaccine Technologies
  • 9.7 Global Vaccine Action Plan by WHO (2011 - 2020)
  • 9.8 Continuous Focus on Effective Communication Strategies

10. ADULT VACCINES MARKET - CHALLENGES

  • 10.1 Hurdles to Optimal use of Licensed Vaccines
    • 10.1.1 Technical Obstacles
    • 10.1.2 Economic obstacles
    • 10.1.3 Cultural Obstacles
  • 10.2 Shortening the Timeline for Vaccine Development
  • 10.3 Complexity of Vaccine Development and Approval System Thwarts Product Development
    • 10.3.1 Legal Obstacles
    • 10.3.2 General Technical Barriers
    • 10.3.3 Economic Barriers
    • 10.3.4 Regulatory Barriers
  • 10.4 Refusal/Resistance to Vaccination
  • 10.5 Vaccine Adverse Event Reporting System
  • 10.6 Vaccine Shortages and Delays
  • 10.7 Obstacles in Vaccine Research and Development
  • 10.8 Barriers to New Entrants in the Vaccines Market

List of Figures:

  • Figure 2-1: Global - Adult Vaccines Market (Million US$), 2007 - 2014
  • Figure 2-2: Global - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
  • Figure 2-3: Global - Number of Adults Vaccinated (Million), 2007 - 2014
  • Figure 2-4: Global - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
  • Figure 3-1: Global Adult Vaccines - Company Wise Market Share (Percent), 2010 - 2014
  • Figure 3-2: Global Adult Vaccines - Forecast for Company Wise Market Share (Percent), 2015 - 2020
  • Figure 3-3: GlaxoSmithKline (GSK) - Adult Vaccines Sales Share (Percent), 2007 - 2014
  • Figure 3-4: GlaxoSmithKline (GSK) - Forecast for Adult Vaccines Sales Share (Percent), 2015 - 2020
  • Figure 3-5: Sanofi Pasteur - Adult Vaccines Sales Share (Percent), 2010 - 2014
  • Figure 3-6: Sanofi Pasteur - Forecast for Adult Vaccines Sales Share (Percent), 2015 - 2020
  • Figure 3-7: Merck - Adult Vaccines Sales Share (Percent), 2010 - 2014
  • Figure 3-8: Merck - Forecast for Adult Vaccines Sales Share (Percent), 2015 - 2020
  • Figure 3-9: Novartis - Adult Vaccines Sales Share (Percent), 2010 - 2014
  • Figure 3-10: Novartis* - Forecast for Adult Vaccines Sales Share (Percent), 2015 - 2020
  • Figure 3-11: Influenza Adult Vaccines - Company Market Share (Percent), 2010 - 2014
  • Figure 3-12: Influenza Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
  • Figure 3-13: Cervical Cancer/HPV Adult Vaccines - Company Market Share (Percent), 2007 - 2014
  • Figure 3-14: Cervical Cancer/HPV Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
  • Figure 3-15: Hepatitis Adult Vaccines - Company Market Share (Percent), 2008 - 2014
  • Figure 3-16: Hepatitis Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
  • Figure 3-17: Pneumococcal Adult Vaccines - Company Market Share (Percent), 2010 - 2014
  • Figure 3-18: Pneumococcal Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
  • Figure 3-19: Meningococcal Adult Vaccines - Company Market Share (Percent), 2010 - 2014
  • Figure 3-20: Meningococcal Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
  • Figure 3-21: DTP Adult Vaccines - Company Market Share (Percent), 2010 - 2014
  • Figure 3-22: DTP Adult Vaccines - Forecast for Company Market Share (Percent), 2015 - 2020
  • Figure 3-23: Region Wise - Adult Vaccines Market Share (Percent), 2011 - 2014
  • Figure 3-24: Region Wise - Forecast for Adult Vaccines Market Share (Percent), 2015 - 2020
  • Figure 4-1: Influenza - Adult Vaccine Market (Million US$), 2007 - 2014
  • Figure 4-2: Influenza - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
  • Figure 4-3: Influenza - Number of Adults Vaccinated (Million), 2007 - 2014
  • Figure 4-4: Influenza - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
  • Figure 4-5: Influenza - Number of Vaccines Doses (Million), 2007 - 2014
  • Figure 4-6: Influenza - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
  • Figure 4-7: Cervical Cancer/ HPV - Adult Vaccine Market (Million US$), 2007 - 2014
  • Figure 4-8: Cervical Cancer/ HPV - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
  • Figure 4-9: Cervical Cancer/ HPV - Number of Adults Vaccinated (Million), 2007 - 2014
  • Figure 4-10: Cervical Cancer/ HPV - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
  • Figure 4-11: Cervical Cancer/ HPV - Number of Vaccines Doses (Million), 2007 - 2014
  • Figure 4-12: Cervical Cancer/ HPV - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
  • Figure 4-13: Zoster Shingles - Adult Vaccine Market (Million US$), 2007 - 2014
  • Figure 4-14: Zoster Shingles - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
  • Figure 4-15: Zoster Shingles - Number of Adults Vaccinated (Million), 2007 - 2014
  • Figure 4-16: Zoster Shingles - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
  • Figure 4-17: Zoster Shingles - Number of Vaccines Doses (Million), 2007 - 2014
  • Figure 4-18: Zoster Shingles - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
  • Figure 4-19: Pneumococcal - Adult Vaccine Market (Million US$), 2010 - 2014
  • Figure 4-20: Pneumococcal - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
  • Figure 4-21: Pneumococcal - Number of Adults Vaccinated (Million), 2010 - 2014
  • Figure 4-22: Pneumococcal - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
  • Figure 4-23: Pneumococcal - Number of Vaccines Doses (Million), 2010 - 2014
  • Figure 4-24: Pneumococcal - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
  • Figure 4-25: Meningococcal - Adult Vaccine Market (Million US$), 2010 - 2014
  • Figure 4-26: Meningococcal - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
  • Figure 4-27: Meningococcal - Number of Adults Vaccinated (Million), 2010 - 2014
  • Figure 4-28: Meningococcal - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
  • Figure 4-29: Meningococcal - Number of Vaccines Doses (Million), 2010 - 2014
  • Figure 4-30: Meningococcal - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
  • Figure 4-31: MMRV - Adult Vaccine Market (Million US$), 2007 - 2014
  • Figure 4-32: MMRV - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
  • Figure 4-33: MMRV - Number of Adults Vaccinated (Million), 2007 - 2014
  • Figure 4-34: MMRV - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
  • Figure 4-35: MMRV - Number of Vaccines Doses (Million), 2007 - 2014
  • Figure 4-36: MMRV - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
  • Figure 4-37: Hepatitis - Adult Vaccine Market (Million US$), 2007 - 2014
  • Figure 4-38: Hepatitis - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
  • Figure 4-38: Hepatitis - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
  • Figure 4-39: Hepatitis - Number of Adults Vaccinated (Million), 2007 - 2014
  • Figure 4-40: Influenza - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
  • Figure 4-41: Hepatitis - Number of Vaccines Doses (Million), 2007 - 2014
  • Figure 4-42: Hepatitis - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
  • Figure 4-43: DTP - Adult Vaccine Market (Million US$), 2010 - 2014
  • Figure 4-44: DTP - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
  • Figure 4-45: DTP - Number of Adults Vaccinated (Million), 2010 - 2014
  • Figure 4-46: DTP - Forecast for Number of Adults Vaccinated (Million), 2015 - 2020
  • Figure 4-47: DTP - Number of Vaccines Doses (Million), 2010 - 2014
  • Figure 4-48: DTP - Forecast for Number of Vaccines Doses (Million), 2015 - 2020
  • Figure 4-49: Travel and Miscellaneous - Adult Vaccine Market (Million US$), 2007 - 2014
  • Figure 4-50: Travel and Miscellaneous - Forecast for Adult Vaccine Market (Million US$), 2015 - 2020
  • Figure 5-1: GlaxoSmithKline (GSK) - Adult Vaccine Sales (Million US$), 2007 - 2014
  • Figure 5-2: GlaxoSmithKline (GSK) - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
  • Figure 5-3: Sanofi Pasteur - Adult Vaccine Sales (Million US$), 2010 - 2014
  • Figure 5-4: Sanofi Pasteur - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
  • Figure 5-5: Sanofi Pasteur - Pipeline Vaccines candidates (Phase III), February 2015
  • Figure 5-6: Sanofi Pasteur - Pipeline Vaccines candidates (Phase II), February 2015
  • Figure 5-7: Sanofi Pasteur - Pipeline Vaccines candidates (Phase I), February 2015
  • Figure 5-8: Merck - Adult Vaccine Sales (Million US$), 2007 - 2014
  • Figure 5-9: Merck - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
  • Figure 5-10: Novartis - Adult Vaccine Sales (Million US$), 2010 - 2014
  • Figure 5-11: Novartis* - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
  • Figure 5-12: Pfizer - Adult Vaccine Sales (Million US$), 2010 - 2014
  • Figure 5-13: Pfizer - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
  • Figure 5-14: Other Companies - Adult Vaccine Sales (Million US$), 2010 - 2014
  • Figure 5-15: Other Companies - Forecast for Adult Vaccine Sales (Million US$), 2015 - 2020
  • Figure 6-1: GlaxoSmithKline (GSK) - Influenza Adult Vaccines Sales (Million US$), 2007 - 2014
  • Figure 6-2: GlaxoSmithKline (GSK) - Forecast for Influenza Adult Vaccines Sales (Million US$), 2015 - 2020
  • Figure 6-3: GlaxoSmithKline (GSK) - Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2007 - 2014
  • Figure 6-4: GlaxoSmithKline (GSK) - Forecast for Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2015 - 2020
  • Figure 6-5: GlaxoSmithKline (GSK) - Hepatitis Adult Vaccines Sales (Million US$), 2007 - 2014
  • Figure 6-6: GlaxoSmithKline (GSK) - Forecast for Hepatitis Adult Vaccines Sales (Million US$), 2015 - 2020
  • Figure 6-7: GlaxoSmithKline (GSK) - DTP Adult Vaccines Sales (Million US$), 2007 - 2014
  • Figure 6-8: GlaxoSmithKline (GSK) - Forecast for DTP Adult Vaccines Sales (Million US$), 2015 - 2020
  • Figure 6-9: Sanofi Pasteur - Influenza Adult Vaccines Sales (Million US$), 2009 - 2014
  • Figure 6-10: Sanofi Pasteur - Forecast for Influenza Adult Vaccines Sales (Million US$), 2015 - 2020
  • Figure 6-11: Sanofi Pasteur - DTP Adult Vaccines Sales (Million US$), 2010 - 2014
  • Figure 6-12: Sanofi Pasteur - Forecast for DTP Adult Vaccines Sales (Million US$), 2015 - 2020
  • Figure 6-13: Sanofi Pasteur - Meningococcal Adult Vaccines Sales (Million US$), 2009 - 2014
  • Figure 6-14: Sanofi Pasteur - Forecast for Meningococcal Adult Vaccines Sales (Million US$), 2015 - 2020
  • Figure 6-15: Merck/CSL - Influenza Adult Vaccines Sales (Million US$), 2010 - 2014
  • Figure 6-16: Merck/CSL - Forecast for Influenza Adult Vaccines Sales (Million US$), 2015 - 2020
  • Figure 6-17: Merck - Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2007 - 2014
  • Figure 6-18: Merck - Forecast for Cervical Cancer/HPV Adult Vaccines Sales (Million US$), 2015 - 2020
  • Figure 6-19: Merck - Zoster Shingles Adult Vaccines Sales (Million US$), 2007 - 2014
  • Figure 6-20: Merck - Forecast for Zoster Shingles Adult Vaccines Sales (Million US$), 2015 - 2020
  • Figure 6-21: Merck - Pneumococcal Adult Vaccines Sales (Million US$), 2007 - 2014
  • Figure 6-22: Merck - Forecast for Pneumococcal Adult Vaccines Sales (Million US$), 2015 - 2020
  • Figure 6-23: Merck - MMRV Adult Vaccines Sales (Million US$), 2007 - 2014
  • Figure 6-24: Merck - Forecast for MMRV Adult Vaccines Sales (Million US$), 2015 - 2020
  • Figure 6-25: Merck - Hepatitis Adult Vaccines Sales (Million US$), 2007 - 2014
  • Figure 6-26: Merck - Forecast for Hepatitis Adult Vaccines Sales (Million US$), 2015 - 2020
  • Figure 6-27: Novartis - Influenza Adult Vaccines Sales (Million US$), 2010 - 2014
  • Figure 6-28: Novartis* - Forecast for Influenza Adult Vaccines Sales (Million US$), 2015 - 2020
  • Figure 6-29: Novartis - Meningococcal Adult Vaccines Sales (Million US$), 2010 - 2014
  • Figure 6-30: GSK (Novartis) - Forecast for Meningococcal Adult Vaccines Sales (Million US$), 2015 - 2020
  • Figure 6-31: Pfizer - Pneumococcal Adult Vaccines Sales (Million US$), 2010 - 2014
  • Figure 6-32: Novartis - Forecast for Pneumococcal Adult Vaccines Sales (Million US$), 2015 - 2020
  • Figure 7-1: United States - Adult Vaccines Market (Million US$), 2011 - 2014
  • Figure 7-2: United States - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
  • Figure 7-3: North America/Caribbean - Adult Vaccines Market (Million US$), 2011 - 2014
  • Figure 7-4: North America/Caribbean - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
  • Figure 7-5: South America - Adult Vaccines Market (Million US$), 2011 - 2014
  • Figure 7-6: South America - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
  • Figure 7-7: Europe - Adult Vaccines Market (Million US$), 2011 - 2014
  • Figure 7-8: Europe - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
  • Figure 7-9: Japan - Adult Vaccines Market (Million US$), 2011 - 2014
  • Figure 7-10: Japan - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
  • Figure 7-11: India - Adult Vaccines Market (Million US$), 2011 - 2014
  • Figure 7-12: India - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
  • Figure 7-13: China - Adult Vaccines Market (Million US$), 2011 - 2014
  • Figure 7-14: China - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
  • Figure 7-15: ROW - Adult Vaccines Market (Million US$), 2011 - 2014
  • Figure 7-16: ROW - Forecast for Adult Vaccines Market (Million US$), 2015 - 2020
  • Figure 9-1: US - Number of Retail Clinics offering Vaccination (Number), 2007 - 2012

List of Tables:

  • Table 3-1: Global - Disease Wise Adults Vaccinated Share (Percent), 2010 - 2014
  • Table 3-2: Global - Forecast for Disease Wise Adults Vaccinated Share (Percent), 2015 - 2020
  • Table 3-3: Global Adult Vaccines - Disease Wise Market Share (Percent), 2010 - 2014
  • Table 3-4: Global Adult Vaccines - Forecast for Disease Wise Market Share (Percent), 2015 - 2020
  • Table 8-1: Worldwide - Major Vaccine Related Acquisitions, (2005 - 2015)
  • Table 9-1: Global - Total Future Deaths Averted through Vaccination (Million), 2011 - 2020
  • Table 9-2: Global Goal-Level Indicators, 2015 & 2020
  • Table 9-3: Improvement Strategies or Requirements - the Joint Commission and the Projects Collaborating Organizations
Back to Top